Examkin

Soru

Zorluk: ZorPreventive Care and Screening

A routine health maintenance evaluation is conducted for a 63-year-old female patient with a complex medical history. She is currently managed for seropositive rheumatoid arthritis with weekly methotrexate and subcutaneous etanercept. She also has type 2 diabetes mellitus, maintained on metformin. The patient reports feeling well with no new complaints. She is a lifelong nonsmoker and exercises moderately three times a week.

A review of her preventive care timeline reveals the following:
- Screening colonoscopy at age 54 showed no abnormalities.
- Mammography 8 months ago was reported as normal.
- Bone mineral density testing via DEXA scan at age 59 demonstrated a T-score of -1.1 at the femoral neck.
- She successfully completed the two-dose recombinant zoster vaccination protocol at age 52.
- Her primary care provider administered the 15-valent pneumococcal conjugate vaccine (PCV15) exactly three months ago during a flare of her arthritis.
- Her tetanus-diphtheria-acellular pertussis (Tdap) booster was administered 5 years ago.

Physical examination today demonstrates stable joint findings with no active synovitis. Hemoglobin A1c is 6.8%.

Based on current guidelines, which of the following is the most appropriate next step in this patient's preventive care?

  1. Administration of the 23-valent pneumococcal polysaccharide vaccine (PPSV23)Cevap
  2. B
    Administration of the 20-valent pneumococcal conjugate vaccine (PCV20)
  3. C
    Administration of the recombinant zoster vaccine (RZV)
  4. D
    Dual-energy x-ray absorptiometry (DEXA) scan
  5. E
    Screening colonoscopy

Cevap

Administration of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is the most appropriate next step, as she is immunocompromised and has completed the required 8-week waiting period following her PCV15 dose.
The correct intervention is the administration of the 23-valent pneumococcal polysaccharide vaccine (PPSV23). The Advisory Committee on Immunization Practices (ACIP) updated guidelines mandate that adults aged 19 years or older who possess an immunocompromising condition (e.g., iatrogenic immunosuppression via methotrexate and etanercept) and receive PCV15 must subsequently receive PPSV23. Crucially, the minimum interval between these doses is reduced from 1 year (for immunocompetent adults) to 8 weeks for immunocompromised individuals. Because the patient received PCV15 three months ago, she has surpassed the 8-week threshold and is due for PPSV23 to complete her series.

Adım Adım Çözüm

1
Analyze the patient's immune status and comorbidities.
The patient has rheumatoid arthritis and is taking methotrexate and etanercept, qualifying her as having an immunocompromising condition.
Immune status directly dictates the choice, sequencing, and minimum intervals of adult vaccinations.
2
Review the patient's pneumococcal vaccination history.
She received PCV15 three months (approximately 12 weeks) ago.
ACIP guidelines require adults initiating vaccination with PCV15 to receive a follow-up dose of PPSV23.
3
Determine the appropriate interval for the follow-up vaccine based on immune status.
For immunocompetent adults, the interval between PCV15 and PPSV23 is at least 1 year. For immunocompromised adults, the interval is shortened to at least 8 weeks.
Immunocompromised patients require expedited broad coverage against pneumococcal serotypes. Since 12 weeks have passed, she is eligible for PPSV23 today.

Anahtar Kavram

Adults with immunocompromising conditions who receive the 15-valent pneumococcal conjugate vaccine (PCV15) should receive a follow-up dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) at a shortened minimum interval of 8 weeks.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Preventive Care and Screening

Bu konudan daha fazla soru